Search results for "osteonecrosi"

showing 10 items of 207 documents

Bone metabolism and clinical study of 44 patients with bisphosphonate-related osteonecrosis of the jaws.

2011

Osteonecrosis of the jaws is a clinical entity described and linked to treatment with bisphosphonates in 2003. Its real incidence is unknown and it could increase due to the large number of patients treated with these drugs, and its cumulative effect on the bone. State of the art knowledge regarding its etiopathogeny, clinical course and suitable treatments is limited. Objectives: To study the clinical characteristics of 44 patients with bisphosphonate-related osteonecrosis of the jaws and the state of their bone mineral metabolism: bone remodeling state, prevalence of fractures, bone mineral density study, and assessment of the different treatment strategies. Design of the Study: Observati…

AdultMalemedicine.medical_treatmentOsteoporosisDentistryOdontologíaBone and BonesBone remodelingBreast cancermedicineHumansProspective StudiesProspective cohort studyGeneral DentistryAgedBone mineralAged 80 and overBisphosphonate-associated osteonecrosis of the jawOral Medicine and Pathologybusiness.industryIncidence (epidemiology)BisphosphonateMiddle Aged:CIENCIAS MÉDICAS [UNESCO]medicine.diseaseCiencias de la saludOtorhinolaryngologyUNESCO::CIENCIAS MÉDICASSurgeryBisphosphonate-Associated Osteonecrosis of the JawFemaleResearch-ArticlebusinessMedicina oral, patologia oral y cirugia bucal
researchProduct

Demographic and behavioural profiles of patients with common oral mucosal lesions by a homogeneity analysis

2012

Objective: The aim of this study is to assess the main oral mucosal lesions (OMLs) within a hospital base and to provide an anamnestic, diagnostic model based on homogeneity analysis of some variables. Methods: The demographic and behavioural data (i.e. gender, age, smoking status, alcohol consumption and therapeutic drug usage) of 1753 patients with at least one OML were considered. Multiple correspondence analysis (MCA) and multivariate tests of the simultaneous marginal homogeneity hypothesis (SMH) were used to analyse the evidence of any differences between the demographic and behavioural profiles relating to OMLs diagnoses. Statistical significance of P<0.05 was chosen. Results: With r…

AdultMalesquamous cell carcinomaAdolescentAlcohol DrinkingHealth BehaviorBurning Mouth SyndromeSettore MED/01 - Statistica MedicaYoung AdultSex FactorsDrug TherapySettore MED/28 - Malattie Odontostomatologichemarginal homogeneity hypothesisoral mucosal lesionHumansBMSChildAgedDemographyAged 80 and overhalitosiBRONJSmokingAge FactorsHalitosisMiddle AgedItalyleukoplakiaChild PreschoolCarcinoma Squamous CellBisphosphonate-Associated Osteonecrosis of the JawFemaleMouth NeoplasmsStomatitis AphthousLeukoplakia OralMouth DiseasesRAS
researchProduct

Osteonecrosi dei mascellari associata a bisfosfonati, denosumab e farmaci anti-angiogenetici nei pazienti oncologici e osteoporotici: diagnosi e tera…

2013

Riassunto Obiettivi Fornire un percorso utile alla diagnosi e al trattamento dell’osteonecrosi delle ossa mascellari (solitamente definita ONJ, OsteoNecrosis of the Jaws). Materiali e metodi Gli autori del lavoro, recentemente estensori e collaboratori – su mandato della Societa Italiana di Chirurgia Maxillo-Facciale (SICMF) e della Societa Italiana di Patologia e Medicina Orale (SIPMO), delle Raccomandazioni clinico-terapeutiche sull’osteonecrosi delle ossa mascellari associata a bisfosfonati e sua prevenzione – hanno esaminato le informazioni scientifiche disponibili in merito alla ONJ associata all’assunzione sia di bisfosfonati sia di denosumab e/o anti-angiogenetici, e revisionato l’ep…

Bisfosfonatibusiness.industryOsteonecrosi dei mascellariAnti-angiogeneticiMedicineOrthodonticsOral SurgeryDenosumabbusinessHumanitiesOsteonecrosi dei mascellari; Bisfosfonati; Anti-angiogenetici; DenosumabOsteonecrosi dei mascellari terapia
researchProduct

Osteonecrosi dei mascellari associata a bisfosfonati, denosumab e farmaci anti-angiogenetici nei pazienti oncologici e osteoporotici: prevenzione den…

2013

Riassunto Obiettivi Proporre protocolli di gestione odontoiatrica per il paziente che assume o che assumera farmaci (per esempio bisfosfonati, denosumab e anti-angiogenetici) correlati all’insorgenza di osteonecrosi dei mascellari (OsteoNecrosis of the Jaws, ONJ). Materiali e metodi Gli autori del lavoro, recentemente estensori e collaboratori – su mandato della Societa Italiana di Chirurgia Maxillo-Facciale (SICMF) e della Societa Italiana di Patologia e Medicina Orale (SIPMO), delle Raccomandazioni clinicoterapeutiche sull’osteonecrosi delle ossa mascellari associata a bisfosfonati e sua prevenzione – hanno esaminato le informazioni scientifiche disponibili in merito alla ONJ (associata a…

Bisfosfonatibusiness.industryOsteonecrosiAnti-angiogeneticiMedicineOrthodonticsDenosumabOral SurgerybusinessHumanitiesOsteonecrosi; Bisfosfonati; Anti-angiogenetici; DenosumabDental Cadmos
researchProduct

Osteonecrosis maxilar y bisfosfonatos: presentación de tres nuevos casos

2006

Los bisfosfonatos están adquiriendo una relevancia terapéutica cada vez mayor, dada su utilidad en el manejo de diversas patologías. Con el incremento de su uso, se están documentando casos de necrosis ósea mandibular, y en menor medida maxilar, de difícil solución y con una importante afectación de la calidad de vida de los pacientes en tratamiento con estos fármacos. El factor que con mayor frecuencia desencadena el proceso es la actuación de los profesionales: odontólogos, estomatólogos y cirujanos orales y maxilofaciales. La previsión, las intervenciones atraumáticas y el tratamiento conservador, parecen ser los medios más adecuados para minimizar la incidencia o resolver las complicaci…

Bisfosfonatosefectos secundariososteonecrosisUNESCO::CIENCIAS MÉDICASOdontología:CIENCIAS MÉDICAS [UNESCO]Ciencias de la salud
researchProduct

Bisfosfonatos y Patología Oral I: aspectos generales y preventivos

2006

Los bisfosfonatos constituyen un grupo de fármacos capaces de modular el recambio óseo y disminuir su remodelado cuando existe una reabsorción excesiva. Por ello están indicados en numerosas patologías óseas como la osteoporosis postmenopáusica o la osteolisis asociada al cáncer de mama o al mieloma múltiple. En los últimos años y a raíz de su utilización masiva se han ido publicando numerosos casos de complicaciones asociadas a su uso. Entre los posibles efectos adversos más importantes se encuentran los orales, con la aparición de ulceraciones y sobre todo los casos de osteonecrosis de los maxilares asociados a esta terapéutica. En esta revisión analizamos las características generales de…

Bisfosofonatosmaxilarprevenciónefectos adversososteonecrosisUNESCO::CIENCIAS MÉDICASOdontología:CIENCIAS MÉDICAS [UNESCO]Ciencias de la salud
researchProduct

Bisphosphonate related osteonecrosis of the jaws in Italy: an observational report of 24 cases

2018

Bisphosphonate osteonecrosis of the jaws Italy observational report
researchProduct

Bisphosphonate-associated Osteonecrosis of the jaw: frequencies (82 cases) from the Western Sicily-Promab e ARNAS

2009

Bisphosphonate-Osteonecrosis of the jaw:
researchProduct

L-PRF application in extraction sockets of bisphosphonate-treated patients: preliminary results

2016

Bisphosphonate-related osteonecrosis of the jaw (BRONJ) is a severe adverse event related to bisphosphonates (BPs) therapy; tooth extraction has been described as the main trigger. Autologous platelet concentrates, such Leukocyte-Platelet Rich Fibrin (L-PRF, Intraspin !) are designed to release platelet growth factors, improving the tissue healing in oral surgery. The aim of this study was to evaluate the efficacy and safety of our dental extraction protocol applied in BPs patients.

Bisphosphonate-related osteonecrosis of the jaw Autologus platelet concentrates Leukocyte-Platelet Rich Fibrin dental extraction
researchProduct

Osteonecrosis in Hodgkin lymphoma treated by BEACOPP

2018

BleomycinAntineoplastic Combined Chemotherapy ProtocolTreatment OutcomeDoxorubicinVincristineProcarbazineOsteonecrosiInternal MedicinePrednisoneCyclophosphamideHodgkin DiseaseEtoposideHuman
researchProduct